SGLT2i drug for heart health in Duchenne muscular dystrophy
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Duchenne muscular dystrophy (by genetic test or muscle biopsy).
- You have some early signs of heart scarring seen on a special MRI (CMR).
- Your heart's pumping ability is normal or only mildly reduced (LVEF above 40%).
- You are between 8 and 18 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called semaglutide (often used for weight management and diabetes) can improve metabolic health in people with Duchenne muscular dystrophy who are overweight. If you join, you may receive the drug or a placebo, and you'll have health checks including MRIs.
This study uses a wearable device to track blood sugar levels and heart rate in people with Duchenne muscular dystrophy. It aims to understand how these factors relate to heart health over time.
This study uses a wearable device to track your blood sugar levels and heart rate patterns over time. It aims to understand how these are related to Duchenne muscular dystrophy (DMD) and may help improve care.
This trial studies whether a medicine called empagliflozin, currently used for diabetes, can help improve heart function in children with Duchenne muscular dystrophy who also have heart muscle weakness. The medicine is given as a pill and aims to slow down the heart damage so children can feel better for longer.
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.